Tag: biolojic

[Biolojic in BioSpace] Interim results from phase 1/2 clinical trial in solid tumor cancers demonstrate Aulos Bioscience’s AU-007 is well tolerated and uniquely reduces regulatory T Cells

May 25, 2023 |

LARKSPUR, Calif.–(BUSINESS WIRE)– Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today shared interim results from an ongoing Phase 1/2 trial of AU-007, as detailed in the online publication of Abstract e14507 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Read...

Read More

[Biolojic in Business Wire] First U.S. patient dosed in Aulos Bioscience’s Phase 1/2 clinical trial of AU-007, a novel IL-2 therapeutic for the treatment of solid tumors

Feb 1, 2023 |

LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that the first patient has been dosed in the United States in its Phase 1/2 clinical trial evaluating AU-007 for the treatment of solid tumors. Read...

Read More

Latest from Twitter

Follow @OurCrowd